

FIG. 1A




FIG. 1B

CL83 pJJG78/CL83 pUC19-600/CL83

CS Fime (hr) 0 0.5 1.5 3 5 24 0 0.5 1.5 3 5 24 0 0.5 1.5 3 5 24





FIG. 2



PUC 19 Frag.2 Frag.2A Frag.2B Frag.2E





1 2 3 4 5 6

FIG. 4






FIG. 5B



FIG. 5A







CS time (hr) 0 1 3 0 1 3





FIG. 7






FIG. 9A




FIG. 9B




FIG. 10A






FIG. 11A




FIG. 12






FIG. 13A



Relative Translation Efficiency (%)






FIG. 13B




FIG. 14A pmm67




FIG. 14B pmm022




FIG. 14(pmm023





FIG. 14D pmm024







FIG. 14F pmm026



HG. 15A





FIG. 15B






FIG. 15D





FIG. 16A

EIC' 1PB







FIG. 16C



Time (min) After Rifampicin Addition

FIG. 16D




FIG. 17A

The first the fit that the term of the three three mark and the flash the fit that the fit the flash the fit the flash the fla


PJJG78 UCUAGAGGGUAUUAAUAAUAAUGAAAGGGGGAAUUCCAAGCUUGGAUCCG ὑλὰὑὑΑΘὑΘὑὑὑΟΑΟ 16S rRNA anti-DB

AUGAAUCACAAAGUGG AUGAAUCACAAAGUGG PINZDB2 UCUAGCCCUUAUUAAUAAUGAAAGGGGGGAAUUAUGAAAUCACAAAGUGG PINZDB1 UCUAGAGGGUAUUAAUAAUGAAAGGGGGAAUUAUGAAUCACAAAGUGG Perfect match-DB 16S rRNA anti-DB PINZDB3 UCUAGCCCUUAUUAAUA---PINZDB4 UCUAGAGGGUAUUAAUA-


FIG. 17B

FIG. 15E


Relative Amount of mRNA



 β -Galactosidase Activity (Miller Units x 10⁻³)



Ratio of β -Galactosidase Synthesis (pINZDB1/pINZ)







FIG. 17E






FIG. 18A







FIG. 18B










FIG. 20B

